AI assistant
Tango Therapeutics, Inc. — Director's Dealing 2021
Aug 13, 2021
32459_dirs_2021-08-12_fba89a73-fc85-415b-aefb-3acfc2d92528.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Tango Therapeutics, Inc. (TNGX)
CIK: 0001819133
Period of Report: 2021-08-10
Reporting Person: Huang Alan (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 135887 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.383 | 2028-04-11 | Common Stock (84930) | Direct | |
| Stock Option (Right to Buy) | $1.383 | 2028-04-11 | Common Stock (110409) | Direct | |
| Stock Option (Right to Buy) | $1.531 | 2029-01-24 | Common Stock (67944) | Direct | |
| Stock Option (Right to Buy) | $1.648 | 2030-01-30 | Common Stock (67944) | Direct | |
| Stock Option (Right to Buy) | $3.503 | 2031-01-28 | Common Stock (95121) | Direct | |
| Stock Option (Right to Buy) | $3.503 | 2031-01-28 | Common Stock (67944) | Direct |
Footnotes
F1: This option shall vest and become exercisable in equally monthly installments over a period of 48 months from January 1, 2018.
F2: This option shall vest and become exercisable in monthly installments over a period of 48 months from April 1, 2018.
F3: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2020, with the remaining option shares vesting in 36 equal monthly installments thereafter.
F4: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2021, with the remaining option shares vesting in 36 equal monthly installments thereafter.
F5: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter.
F6: This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter.